Differentiating the roles of STAT5B and STAT5A in human CD4(+) T cells
Carregando...
Citações na Scopus
40
Tipo de produção
article
Data de publicação
2013
Título da Revista
ISSN da Revista
Título do Volume
Editora
ACADEMIC PRESS INC ELSEVIER SCIENCE
Autores
JENKS, Jennifer A.
SEKI, Scott
KANAI, Takahiro
HUANG, Jennifer
MORGAN, Alexander A.
NATH, Ruhi
BUCAYU, Robert
WIT, Jan M.
AL-HERZ, Waleed
Citação
CLINICAL IMMUNOLOGY, v.148, n.2, p.227-236, 2013
Resumo
STAT5A and STAT5B are highly homologous proteins whose distinctive roles in human immunity remain unclear. However, STAT5A sufficiency cannot compensate for STAT5B defects, and human STAT5B deficiency, a rare autosomal recessive primary immunodeficiency, is characterized by chronic lung disease, growth failure and autoimmunity associated with regulatory T cell (Treg) reduction. We therefore hypothesized that STAT5A and STAT5B play unique roles in CD4(+) T cells. Upon knocking down STAT5A or STAT5B in human primary T cells, we found differentially regulated expression of FOXP3 and IL-2R in STAT5B knockdown T cells and down-regulated Bcl-X only in STAT5A knockdown T cells. Functional ex vivo studies in homozygous STAT5B-deficient patients showed reduced FOXP3 expression with impaired regulatory function of STAT5B-null Treg cells, also of increased memory phenotype. These results indicate that STAT5B and STAT5A act partly as non-redundant transcription factors and that STAT5B is more critical for Treg maintenance and function in humans.
Palavras-chave
STAT5, Regulatory T cells (Treg), T cell development
Referências
- Antov A, 2003, J IMMUNOL, V171, P3435
- Booth NJ, 2010, J IMMUNOL, V184, P4317, DOI 10.4049/jimmunol.0903781
- Boucheron C, 1998, J BIOL CHEM, V273, P33936, DOI 10.1074/jbc.273.51.33936
- Cheng GY, 2011, IMMUNOL REV, V241, P63, DOI 10.1111/j.1600-065X.2011.01004.x
- Cohen AC, 2006, J IMMUNOL, V177, P2770
- Fontenot JD, 2003, NAT IMMUNOL, V4, P330, DOI 10.1038/ni904
- Gesbert F, 2000, BLOOD, V96, P2269
- Grimley PM, 1999, CYTOKINE GROWTH F R, V10, P131, DOI 10.1016/S1359-6101(99)00011-8
- Haines CJ, 2009, J EXP MED, V206, P275, DOI 10.1084/jem.20080996
- Hazenberg MD, 2000, NAT MED, V6, P1036
- Huehn J, 2009, NAT REV IMMUNOL, V9, P83, DOI 10.1038/nri2474
- Hwa V, 2011, BEST PRACT RES CL EN, V25, P61, DOI 10.1016/j.beem.2010.09.003
- Johnston RJ, 2012, J EXP MED, V209, P243, DOI 10.1084/jem.20111174
- Joung YH, 2007, BIOCHEM BIOPH RES CO, V358, P733, DOI 10.1016/j.bbrc.2007.04.201
- Kanai Takahiro, 2012, Front Immunol, V3, P234, DOI 10.3389/fimmu.2012.00234
- Kofoed EM, 2003, NEW ENGL J MED, V349, P1139, DOI 10.1056/NEJMoa022926
- Miura Y, 2004, BLOOD, V104, P2187, DOI 10.1182/blood-2004-03-1040
- Nadeau K, 2011, J PEDIATR-US, V158, P701, DOI 10.1016/j.jpeds.2010.12.042
- Nadeau K, 2010, J ALLERGY CLIN IMMUN, V126, P845, DOI 10.1016/j.jaci.2010.08.008
- Passerini L, 2008, INT IMMUNOL, V20, P421, DOI 10.1093/intimm/dxn002
- Snow JW, 2003, J IMMUNOL, V171, P5042
- Soldaini E, 2000, MOL CELL BIOL, V20, P389
- Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0
- Torgerson TR, 2008, IMMUNOL ALLERGY CLIN, V28, P315, DOI 10.1016/j.iac.2008.02.002
- Tran DQ, 2007, BLOOD, V110, P2983, DOI 10.1182/blood-2007-06-094656
- Vukmanovic-Stejic M, 2006, J CLIN INVEST, V116, P2423, DOI 10.1172/JCI28941
- Walenkamp MJE, 2007, EUR J ENDOCRINOL, V156, P155, DOI 10.1530/eje.1.02327
- Wang J, 2007, EUR J IMMUNOL, V37, P129, DOI 10.1002/eji.200636435
- Yao Z, 2007, BLOOD, V109, P4368, DOI 10.1182/blood-2006-11-055756
- Yao ZJ, 2006, P NATL ACAD SCI USA, V103, P1000, DOI 10.1073/pnas.0507350103
- Yu GP, 2009, CLIN IMMUNOL, V131, P240, DOI 10.1016/j.clim.2008.12.006
- Zorn E, 2006, BLOOD, V108, P1571, DOI 10.1182/blood-2006-02-004747